Clinical trial NCT00945477: Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Official title: A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: Illinois CancerCare, P.C.
Sponsor class: OTHER
First posted: 2009-07-24
Enrollment: 11
Sex: MALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer.

* Vascular endothelial growth factor (VEGF) expression is low in normal prostate tissue, but markedly increased in tumor tissues, and has a positive association with tumor stage and grade
* Plasma VEGF levels are significantly elevated in patients with hormone refractory prostate cancer (HRPC) compared to those patients with localized disease and have been associated with disease progression in other cancer patient population.
* The Cancer and Leukemic Group-B demonstrated that VEGF levels correlate with survival.

Pazopanib is a potent multi-target receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptors.

Detailed description: VEGF expression is low in all normal prostate tissue, but markedly increased in tumor tissue, and has a positive association with MVD (micro vessel density) tumor stage, grade, and disease-specific survival in patients with prostate cancer. VEGF is known to be under the influence of HIF-1α, which is also up-regulated in the majority of prostate cancer tissue. It has been shown that complete androgen blockade down-regulates VEGF expression via the HIF-1α pathway with concomitant up-regulation of thrombospondin and induction of endothelial cell apoptosis. The VEGF pathway appears to be the dominant vascular formation pathway in prostate cancer with bFGF having a lesser role.

Pazopanib , a hydrochloride salt, is a small molecule inhibitor of several tyrosine kinases, ie: VEGF 1, 2, 3, c-KIT and platelet-derived growth factor receptors. The broad blockade of the VEGF receptors should interfere with the VEGF/VEGF-receptor pathway, and have an impact on cell growth.

According to the NCCN guidelines , first line therapy for metastatic prostate cancer is considered total androgen blockade, either utilizing orchiectomy and/or LH/RH agonists plus Casodex.

Second line therapy would depend on the patient's response to first line therapy, urgency of a response, and the location of metastatic disease.

Pazopanib has been explored in several settings. It has recently been looked at with Bicalutamide in hormone refractory prostate cancer. The second study was with earlier disease, i.e. D-0 relapse androgen-sensitive patients. The University of Chicago has a study looking at the sub-population of prostate cancer patients that have a "chemical relapse" in which patients are given one shot of Lupron, and if the PSA is adequately suppressed, the patients are randomized between pazopanib and placebo.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of adenocarcinoma of the prostate histology, currently on total androgen blockage with a bicalutamide.
2. Subjects must provide written informed consent prior to administration of pazopanib or the performance of any study-specific procedures or assessments, and must be willing to comply with treatment and follow up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol. Note: It is not necessary that informed consent be obtained within the protocol-specified screening window.
3. Received no prior second line hormone therapy or any chemotherapy. No prior bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or metastatic prostate cancer.
4. Must have metastatic diagnosis, meaning disease beyond the prostate gland.
5. A progressing PSA of ≥ 3, the PSA will be measured in ≥ 14 days.
6. KPS of ≥ 70
7. Age ≥ 18 years old
8. Adequate organ system functions:

   * Absolute neutrophil count (ANC) ≥ 1.5 X 109/L
   * Hemoglobin ≥ 9 g/dL
   * Platelets ≥ 100 X 109/L
   * International normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN)
   * Partial thromboplastin time (PTT) ≤ 1.2 X ULN
   * Total bilirubin ≤ 1.5 X ULN
   * AST and ALT ≤ 2.5 X ULN
   * Calculated creatinine clearance ≥ 30 mL/min
   * Urine Protein to Creatinine Ratio (UPC)2 \< 1
   * Total serum calcium concentration \< 12.0mg/dL

     * Subjects may not have had a transfusion within 7 days of screening assessment.
     * If UPC ≥ 1, then a 24-hour urine protein must be assessed. Subjects must have a 24-hour urine protein value \< 1 g to be eligible.
9. Left ventricular ejection fraction (LVEF) ≥ 55% as assessed by echocardiography or multigated acquisition (MUGA) scan. The same modality used at baseline must be applied for subsequent evaluations.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

1. History of another malignancy.

   Note: Subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
2. History or clinical evidence of central nervous system (CNS) metastases.

   Note: Subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:
   * Are asymptomatic and,
   * Have had no evidence of active CNS metastases for ≥ 6 months prior to enrollment and,
   * Have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC).
3. Clinically significant gastrointestinal abnormalities including, but not limited to:

   * Malabsorption syndrome,
   * Major resection of the stomach or small bowel that could affect the absorption of study drug,
   * Active peptic ulcer disease,
   * Inflammatory bowel disease,
   * Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation,
   * History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.
4. Presence of uncontrolled infection.
5. Prolongation of corrected QT interval (QTc) \> 480 milliseconds (msecs).
6. History of any one or more of the following cardiovascular conditions within the past 12 months:

   * Cardiac angioplasty or stenting,
   * Myocardial infarction,
   * Unstable angina,
   * Symptomatic peripheral vascular disease,
   * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
7. History of cerebrovascular accident (CVA) including transient ischemic attack (TIA).
8. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible.
9. Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥150mmHg or diastolic blood pressure (DBP) of ≥ 90 mmHg\].

   Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Blood pressure must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from each blood pressure assessment must be \< 150/90mmHg in order for a subject to be eligible for the study. See Section 6.3.2 for instruction on blood pressure measurement and obtaining mean blood pressure values.
10. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
11. Evidence of active bleeding or bleeding diathesis
12. Hemoptysis within 6 weeks of first dose of study drug.
13. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study.
14. Prohibited medications within 28 days unless the half-life of the medication is longer than 28 days, will not be permitted.
15. Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
16. Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors (e.g., bevacizumab, sunitinib, sorafenib, etc), or are mTOR inhibitors (eg. temsirolimus, everolimus, etc).
17. Is now undergoing and/or has undergone in the last 4 weeks immediately prior to first dose of study drug, (surgery, tumor embolization, chemotherapy, radiation therapy, immunotherapy, or biological therapy)
18. Any ongoing toxicity from prior anti-cancer therapy that is \> Grade 1 and/or that is progressing in severity.
19. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.

Primary outcomes:
measure: Response Rate at 12 Weeks
timeFrame: 12 weeks
Secondary outcomes:
measure: Number Adverse Events, Grades 1-5 Using NCI-CTCAE v 3.0
timeFrame: 0-12 weeks
Other outcomes:
Locations:
city: Bloomington
country: United States
facility: Illinois CancerCare
state: Illinois
city: Ottawa
country: United States
facility: Illinois CancerCare
state: Illinois
city: Pekin
country: United States
facility: Illinois CancerCare
state: Illinois
city: Peoria
country: United States
facility: Illinois Cancer Care
state: Illinois
Study officials:
References: